Zymeron

Zymeron is a research-based biotechnology company headquartered in Research Triangle Park, North Carolina. The company specializes in the development of innovative health technologies, including precision therapeutics, diagnostics, and medical countermeasures. Its core research focus includes myeloprotective, cardioprotective, and neuroprotective drugs designed to manage conditions such as chemotherapy-induced myelosuppression and acute radiation syndrome. Zymeron utilizes proprietary platforms like its bone marrow drug delivery technology, which employs peptide drug conjugates to protect hematopoietic stem and progenitor cells, as well as formulation technologies that enhance the solubility of small molecule drugs for emergency and clinical use. Additionally, the company operates an innovation engine that advances diagnostic solutions, including handheld integrated platforms for rapid pathogen detection and automated assays for miRNA analysis.

By bridging critical gaps in pharmaceutical science, Zymeron aims to transform clinical management from reactive to preventive, ultimately improving patient quality of life. The company actively collaborates with government agencies, including the Department of Defense and the Department of Health and Human Services, to address national health and defense needs. Through these strategic partnerships, Zymeron commercializes advanced materials and technologies, including its spinoff division, MicroFAST Dx, which focuses on point-of-care and at-home diagnostic capabilities. The company's multidisciplinary team leverages diverse expertise to develop disruptive innovations that provide step-change performance in areas of significant unmet clinical need.